Trial Profile
Nivolumab Plus Stereotactic Body Radiotherapy (SBRT) in II and III Line of Patients With Metastatic Renal Cell Carcinoma (mRCC)
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 18 May 2022
Price :
$35
*
At a glance
- Drugs Nivolumab (Primary)
- Indications Renal cell carcinoma
- Focus Therapeutic Use
- Acronyms NIVES
- 29 Aug 2021 Status changed from active, no longer recruiting to completed.
- 08 Jun 2021 Results of exploratory analysis the correlation between PD-L1 expression and clinical outcomes, presented at the 57th Annual Meeting of the American Society of Clinical Oncology.
- 29 Jul 2020 Planned End Date changed from 14 Jul 2020 to 14 Jul 2021.